High serum Aβ and vascular risk factors in first-degree relatives of alzheimer's disease patients

Molecular Medicine

Volumn 15, Issue 3-4, 2009, Pages 95-100

  Abdullah, Laila ^a   Luis, Cheryl ^a   Paris, Daniel ^a   Ait ghezala, Ghania ^a   Mouzon, Benoit ^a   Allen, Elizabeth ^b   Parrish, Julia ^a   Mullan, Myles A ^a   Ferguson, Scott ^a   Wood, Marcie ^a   Crawford, Fiona ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG USE; ETHNICITY; FAMILY HISTORY; FEMALE; GENDER; GENOTYPE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; BLOOD; BLOOD VESSEL; FAMILY; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD VESSELS; FAMILY; FEMALE; HUMANS; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 64549109277     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2008.00118     Document Type: Article

References (40)

1. Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. (2000) Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr. Opin. Neurol. 13:377-84.
2. Mayeux R, et al. (2003) Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 61:1185-9.
3. Casoli T, et al. (2007) Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1096:170-8.
4. 1-40 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5:655-60.
5. Blasko I, et al. (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and ho-mocysteine. Neurobiol. Aging. 29:1-11.
6. Abdullah L, et al. (2007) The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels. Neurosci. Lett. 428:53-8.
7. Luis CA, et al. (2008) Serum β-amyloid levels correlate with cognitive impairment. Neuropsychol Dev. Cogn. B. Aging Neuropsychol. Cogn. 15:1-16.
8. Ertekin-Taner N, et al. (2000) Linkage of plasma Aβp42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 290:2303-4.
9. Ertekin-Taner N, et al. (2008) Plasma amyloid β protein is elevated in late-onset Alzheimer disease families. Neurology 70:596-606.
10. De Jonghe C, et al. (1999) Evidence that Aβ42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phe-notype. Neurobiol. Dis. 6:280-7.
11. Scheuner D, et al. (1996). Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:864-70.
12. Sleegers K, et al. (2004). Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain. 127(Pt 7):1641-9.
13. Houlden H, et al. (1994). Confirmation that familial clustering and age of onset in late onset Alzheimer's disease are determined at the apolipopro-tein E locus. Neurosci. Lett. 174:222-4.
14. Evans DA, et al. (1997). Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 277:822-4.
15. Rosendorff, C, Beeri MS, Silverman JM. (2007). Cardiovascular risk factors for Alzheimer's disease. Am. J. Geriatr. Cardiol. 16:143-9.
16. Skoog I, et al. (1996). 15-year longitudinal study of blood pressure and dementia. Lancet. 347:1141-5.
17. Launer LJ, et al. (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21:49-55.
18. Kivipelto M, et al. (2001). Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322:1447-51.
19. Notkola IL, et al. (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17:14-20.
20. Gentile MT, et al. (2009) β-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol. Aging 30:222-8.
21. Deane R, Wu Z, Zlokovic BV. (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl 1):2628-31.
22. Wenham PR, Newton CR, Price WH. (1991) Analysis of apolipoprotein E genotypes by the Amplification Refractory Mutation System. Clin. Chem. 37:241-4.
23. Caselli RJ, et al. (2007) Cognitive domain decline in healthy apolipoprotein E epsilon4 homozy-gotes before the diagnosis of mild cognitive impairment. Arch. Neurol. 64:1306-11.
24. Cosentino S, et al. (2008) APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 70(19 Pt 2):1842-9.
25. Rockwood K. (2006) Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta. Neurol. Scand. Suppl. 185:71-7.
26. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. (2008) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry. 2008, Oct 17 [Epub ahead of print].
27. Sparks DL, et al. (2008) Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 5:416-21.
28. Wolozin B, et al. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5:20.
29. Hoglund K, Blennow K. (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid pep-tide levels: implications for Alzheimer's disease. CNS Drugs 21:449-62.
30. Blasko I, et al. (2008) Effects of medications on plasma amyloid β (Aβ) 42: longitudinal data from the VITA cohort. J. Psychiatr. Res. 42:946-55.
31. Sousa M, Berglund ML, Saraiva MJ. (2000) Transthyretin in high density lipoproteins: association with apolipoprotein A-I. J. Lipid Res. 41:58-65.
32. Matsubara E, Frangione B, Ghiso J. (1995) Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J. Biol. Chem. 270:7563-7.
33. Koudinov A, Matsubara E, Frangione B, and Ghiso J. (1994) The soluble form of Alzheimer's amyloid β protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem. Biophys. Res. Commun. 205:1164-71.
34. Wilson LM, et al. (2006). High density lipoproeins bind Aβ and apolipoprotein C-II amyloid fibrils. J. Lipid Res. 47:755-60.
35. Balakrishnan K, et al. (2005). Plasma Aβ42 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8:269-82.
36. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. (2002) Serum creatinine levels correlate with plasma amyloid amyloid β protein Alzheimer Dis. Assoc. Disord. 16:187-90.
37. Weggen S, et al. (2001). A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414:212-6.
38. Szekely CA, et al. (2008) No advantage of Aβ 42- lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70:2291-8.
39. Green RC, Schneider LS, Hendrix SB, Zavitz KH, Swabb E. (2008) Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multi-center phase 3 trial. Alzheimers Dement. 4(4 Suppl):T165.
40. Breitner JCS (2008). Onset of Alzheimer's dementia occurs commonly without prior cognitive impairment: results from the Alzheimer's disease anti-inflammatory prevention trial (ADAPT). Alzheimers Dement. 4(4 Suppl):T130-1.